TNFRSF17 and B-cell chronic lymphocytic leukemia: Moreover, Friedman et al. [42], who designed the CAR-T-BCMA (bb2121) [26], identified BCMA expression in primary lymphoma and CLL cells and confirmed the high efficacy of CAR-T-BCMA against models of MM, Burkitt lymphoma, and mantle cell lymphoma, suggesting that this CAR construct could be also efficient for these malignancies.